Skip to content

Study · Non-randomized trial · n = 10 · 2019

8 results

The effect of a GnRH antagonist on follicle maturation in normal women.

Pousias S, Messini CI, Anifandis G, Sveronis G, Georgoulias P, Daponte A, Messinis IE, Dafopoulos K

Reproductive biomedicine online11 Mar 2019Cited by 4 (Europe PMC)

PMID31129014 (opens in a new tab)DOI10.1016/j.rbmo.2019.03.100 (opens in a new tab)PepBankPUB-31129014
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In normally cycling women, serum FSH remained stable during ganirelix treatment.

    In plain wordsIn normally cycling women, serum FSH remained stable during ganirelix treatment.

    Peptide
    Ganirelix
    Outcome
    No significant changeSerum FSH stability
    Study

    n = 10

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · subcutaneous · from cycle day 2 until the day of the endogenous LH surge onset in cycle 1As given in this study (human).

    Source sentences

    Summary
    During treatment with ganirelix, serum FSH and oestradiol concentrations remained stable, while those of LH decreased significantly on days 3, 4, 7 and 9 (P < 0.05) compared with controls.
    2 context sentences
    Summary · context
    Ten normally cycling women were investigated during two menstrual cycles, i.e. cycle 1 (control) and cycle 2 (ganirelix).
    Summary · context
    During cycle 2, all women were given 0.25 mg/day subcutaneous injections of the GnRH antagonist ganirelix from day 2 until the day of the endogenous LH surge onset in cycle 1.
  2. 02HumanNon-randomized trialEfficacy outcome

    In normally cycling women, serum oestradiol remained stable during ganirelix treatment.

    In plain wordsIn normally cycling women, serum oestradiol remained stable during ganirelix treatment.

    Peptide
    Ganirelix
    Outcome
    No significant changeSerum oestradiol stability
    Study

    n = 10

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · subcutaneous · from cycle day 2 until the day of the endogenous LH surge onset in cycle 1As given in this study (human).

    Source sentences

    Summary
    During treatment with ganirelix, serum FSH and oestradiol concentrations remained stable, while those of LH decreased significantly on days 3, 4, 7 and 9 (P < 0.05) compared with controls.
    2 context sentences
    Summary · context
    Ten normally cycling women were investigated during two menstrual cycles, i.e. cycle 1 (control) and cycle 2 (ganirelix).
    Summary · context
    During cycle 2, all women were given 0.25 mg/day subcutaneous injections of the GnRH antagonist ganirelix from day 2 until the day of the endogenous LH surge onset in cycle 1.
  3. 03HumanNon-randomized trialEfficacy outcome

    In normally cycling women, ganirelix reduced LH on days 3, 4, 7 and 9 compared with control cycles.

    In plain wordsIn normally cycling women, ganirelix lowered LH compared with control cycles.

    Peptide
    Ganirelix
    Outcome
    DecreaseSerum LH versus control
    Study

    n = 10

    Comparator
    Untreated control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · subcutaneous · from cycle day 2 until the day of the endogenous LH surge onset in cycle 1As given in this study (human).

    Source sentences

    Summary
    During treatment with ganirelix, serum FSH and oestradiol concentrations remained stable, while those of LH decreased significantly on days 3, 4, 7 and 9 (P < 0.05) compared with controls.
    2 context sentences
    Summary · context
    Ten normally cycling women were investigated during two menstrual cycles, i.e. cycle 1 (control) and cycle 2 (ganirelix).
    Summary · context
    During cycle 2, all women were given 0.25 mg/day subcutaneous injections of the GnRH antagonist ganirelix from day 2 until the day of the endogenous LH surge onset in cycle 1.
  4. 04HumanNon-randomized trialEfficacy outcome

    In normally cycling women, LH showed no significant within-cycle variation during ganirelix treatment.

    In plain wordsIn normally cycling women, LH showed no significant variation within the ganirelix cycle.

    Peptide
    Ganirelix
    Outcome
    No significant changeWithin-cycle LH variation
    Study

    n = 10

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · subcutaneous · from cycle day 2 until the day of the endogenous LH surge onset in cycle 1As given in this study (human).

    Source sentences

    Summary
    Nevertheless, there was no significant within-cycle variation in LH concentrations.
    2 context sentences
    Summary · context
    Ten normally cycling women were investigated during two menstrual cycles, i.e. cycle 1 (control) and cycle 2 (ganirelix).
    Summary · context
    During cycle 2, all women were given 0.25 mg/day subcutaneous injections of the GnRH antagonist ganirelix from day 2 until the day of the endogenous LH surge onset in cycle 1.
  5. 05HumanNon-randomized trialEfficacy outcome

    In normally cycling women, no follicle maturation occurred from day 10 during ganirelix treatment, unlike control cycles.

    In plain wordsIn normally cycling women, follicle maturation stopped from day 10 during ganirelix treatment, unlike control cycles.

    Peptide
    Ganirelix
    Outcome
    DecreaseFollicle maturation
    Study

    n = 10

    Comparator
    Untreated control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · subcutaneous · from cycle day 2 until the day of the endogenous LH surge onset in cycle 1As given in this study (human).

    Source sentences

    Summary
    From day 10 onwards, no follicle maturation was observed in cycle 2, in contrast to cycle 1.
    2 context sentences
    Summary · context
    Ten normally cycling women were investigated during two menstrual cycles, i.e. cycle 1 (control) and cycle 2 (ganirelix).
    Summary · context
    During cycle 2, all women were given 0.25 mg/day subcutaneous injections of the GnRH antagonist ganirelix from day 2 until the day of the endogenous LH surge onset in cycle 1.
  6. 06HumanNon-randomized trialEfficacy outcome

    In normally cycling women, ovulation was delayed at least one week in eight women during the ganirelix cycle.

    In plain wordsIn normally cycling women, ovulation was delayed at least one week in eight women during the ganirelix cycle.

    Peptide
    Ganirelix
    Outcome
    IncreaseDelayed ovulation
    Study

    n = 10

    Comparator
    Untreated control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · subcutaneous · from cycle day 2 until the day of the endogenous LH surge onset in cycle 1As given in this study (human).

    Measurements

    Women with delayed ovulation
    8 women
    ganirelix cycle

    Source sentences

    Summary
    In cycle 2, ovulation was delayed by at least 1 week in eight women.
    2 context sentences
    Summary · context
    Ten normally cycling women were investigated during two menstrual cycles, i.e. cycle 1 (control) and cycle 2 (ganirelix).
    Summary · context
    During cycle 2, all women were given 0.25 mg/day subcutaneous injections of the GnRH antagonist ganirelix from day 2 until the day of the endogenous LH surge onset in cycle 1.
  7. 07HumanNon-randomized trialEfficacy outcome

    In normally cycling women, follicle growth occurred in only one woman during ganirelix treatment.

    In plain wordsIn normally cycling women, follicle growth occurred in only one woman during ganirelix treatment.

    Peptide
    Ganirelix
    Outcome
    Not applicableFollicle growth during treatment
    Study

    n = 10

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · subcutaneous · from cycle day 2 until the day of the endogenous LH surge onset in cycle 1As given in this study (human).

    Measurements

    Women with follicle growth during ganirelix
    1 women
    ganirelix cycle

    Source sentences

    Summary
    Follicle growth and ovulation occurred in only one woman while on ganirelix treatment.
    2 context sentences
    Summary · context
    Ten normally cycling women were investigated during two menstrual cycles, i.e. cycle 1 (control) and cycle 2 (ganirelix).
    Summary · context
    During cycle 2, all women were given 0.25 mg/day subcutaneous injections of the GnRH antagonist ganirelix from day 2 until the day of the endogenous LH surge onset in cycle 1.
  8. 08HumanNon-randomized trialEfficacy outcome

    In normally cycling women, ovulation occurred in only one woman during the ganirelix cycle, compared with 9 of 10 women in the control cycle.

    In plain wordsIn normally cycling women, ovulation occurred in only one woman during the ganirelix cycle, compared with 9 of 10 in the control cycle.

    Peptide
    Ganirelix
    Outcome
    DecreaseOvulation during treatment
    Study

    n = 10

    Comparator
    Untreated control cycle
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/day · subcutaneous · from cycle day 2 until the day of the endogenous LH surge onset in cycle 1As given in this study (human).

    Measurements

    Women who ovulated
    1 women
    ganirelix cycle
    Women who ovulated
    9 women
    control cycle, of 10 women

    Source sentences

    Summary
    Follicle growth and ovulation occurred in only one woman while on ganirelix treatment.
    3 context sentences
    Summary · context
    Ovulation occurred in 9 of 10 women in cycle 1.
    Summary · context
    Ten normally cycling women were investigated during two menstrual cycles, i.e. cycle 1 (control) and cycle 2 (ganirelix).
    Summary · context
    During cycle 2, all women were given 0.25 mg/day subcutaneous injections of the GnRH antagonist ganirelix from day 2 until the day of the endogenous LH surge onset in cycle 1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.